{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:04:06Z","timestamp":1789826646819,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8207011007"],"award-info":[{"award-number":["8207011007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402145"],"award-info":[{"award-number":["82402145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200152"],"award-info":[{"award-number":["82200152"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03592-x","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:06:27Z","timestamp":1789823187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TSPAN32 enhances CAR-T cell potency by assembling IL-2 receptor complex and amplifying its intracellular signal transduction"],"prefix":"10.1038","author":[{"given":"Yuanyuan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bochuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huandi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-2140","authenticated-orcid":false,"given":"Yiguo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"3592_CR1","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021;124:1759\u201376.","journal-title":"Br J Cancer"},{"key":"3592_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2019.07.017","volume":"462","author":"X Jiang","year":"2019","unstructured":"Jiang X, Xu J, Liu M, Xing H, Wang Z, Huang L, et al. Adoptive CD8+ T cell therapy against cancer: challenges and opportunities. Cancer Lett. 2019;462:23\u201332.","journal-title":"Cancer Lett"},{"key":"3592_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2020","unstructured":"Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2020;18:842\u201359.","journal-title":"Cell Mol Immunol"},{"key":"3592_CR4","doi-asserted-by":"crossref","unstructured":"Zhao, Y, Deng, J, Rao, S, Guo, S, Shen, J, Du, F, et al. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022;14:4160.","DOI":"10.3390\/cancers14174160"},{"key":"3592_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","volume":"16","author":"N Gong","year":"2021","unstructured":"Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ, et al. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16:25\u201336.","journal-title":"Nat Nanotechnol"},{"key":"3592_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"38","author":"X Ma","year":"2020","unstructured":"Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol. 2020;38:448\u201359.","journal-title":"Nat Biotechnol"},{"key":"3592_CR7","doi-asserted-by":"crossref","unstructured":"Watanabe N, Mo F, McKenna MK. Impact of manufacturing procedures on CAR T cell functionality. Front Immunol 2022;13:876339.","DOI":"10.3389\/fimmu.2022.876339"},{"key":"3592_CR8","doi-asserted-by":"crossref","unstructured":"Zhang DKY, Adu-Berchie K, Iyer S, Liu Y, Cieri N, Brockman JM, et al. Enhancing CAR-T cell functionality in a patient-specific manner. Nat Commun 2023;14(1):506.","DOI":"10.1038\/s41467-023-36126-7"},{"key":"3592_CR9","doi-asserted-by":"crossref","unstructured":"Kouro, T, Himuro, H, Sasada, T Exhaustion of CAR T cells: potential causes and solutions. J Transl Med 2022;20:239.","DOI":"10.1186\/s12967-022-03442-3"},{"key":"3592_CR10","doi-asserted-by":"crossref","unstructured":"Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S. CD8+ T cell exhaustion in cancer. Front Immunol. 2021;12:715234.","DOI":"10.3389\/fimmu.2021.715234"},{"key":"3592_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2021","unstructured":"Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2021;22:209\u201323.","journal-title":"Nat Rev Immunol"},{"key":"3592_CR12","doi-asserted-by":"crossref","unstructured":"Catakovic K, Klieser E, Neureiter D, Geisberger R. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Communication and Signaling. 2017;15:1.","DOI":"10.1186\/s12964-016-0160-z"},{"key":"3592_CR13","doi-asserted-by":"crossref","unstructured":"Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T Cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 2020;8:17.","DOI":"10.3389\/fcell.2020.00017"},{"key":"3592_CR14","doi-asserted-by":"crossref","unstructured":"Zhu X, Li Q, Zhu X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biol. 2022;10:1034257.","DOI":"10.3389\/fcell.2022.1034257"},{"key":"3592_CR15","doi-asserted-by":"crossref","unstructured":"Espie D, Donnadieu E. New insights into CAR T cell-mediated killing of tumor cells. Front Immunol. 2022;13:1016208.","DOI":"10.3389\/fimmu.2022.1016208"},{"key":"3592_CR16","doi-asserted-by":"crossref","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SMJ, Rahbarizadeh F. Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero? Front Immunol. 2022;13:795164.","DOI":"10.3389\/fimmu.2022.795164"},{"key":"3592_CR17","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/s00262-020-02651-3","volume":"69","author":"Y Che","year":"2020","unstructured":"Che Y, Yang Y, Suo J, An Y, Wang X. Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer. Cancer Immunol Immunother. 2020;69:2651\u201364.","journal-title":"Cancer Immunol Immunother"},{"key":"3592_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","volume":"58","author":"RJ Davis","year":"2016","unstructured":"Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016;58:59\u201370.","journal-title":"Oral Oncol"},{"key":"3592_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, et al. Enhanced CAR\u2013T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365:162\u20138.","journal-title":"Science"},{"key":"3592_CR20","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148\u20133165.e20.","journal-title":"Cell"},{"key":"3592_CR21","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.4049\/jimmunol.0902867","volume":"185","author":"KH Gartlan","year":"2010","unstructured":"Gartlan KH, Belz GT, Tarrant JM, Minigo G, Katsara M, Sheng KC, et al. A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity. J Immunol. 2010;185:3158\u201366.","journal-title":"J Immunol"},{"key":"3592_CR22","doi-asserted-by":"crossref","unstructured":"Garcia-Mayea Y, Mir C, Carballo L, S\u00e1nchez-Garc\u00eda A, Bataller M, LLeonart ME. TSPAN1, a novel tetraspanin member highly involved in carcinogenesis and chemoresistance. Biochimica et Biophysica Acta (BBA)\u2014Rev Cancer. 2022;1877:188674.","DOI":"10.1016\/j.bbcan.2021.188674"},{"key":"3592_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nrm1736","volume":"6","author":"ME Hemler","year":"2005","unstructured":"Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6:801\u201311.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3592_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00430-020-00673-3","volume":"209","author":"D Kummer","year":"2020","unstructured":"Kummer D, Steinbacher T, Schwietzer MF, Th\u00f6lmann S, Ebnet K. Tetraspanins: integrating cell surface receptors to functional microdomains in homeostasis and disease. Med Microbiol Immunol. 2020;209:397\u2013405.","journal-title":"Med Microbiol Immunol"},{"key":"3592_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/19336918.2015.1005465","volume":"9","author":"X Jiang","year":"2015","unstructured":"Jiang X, Zhang J, Huang Y. Tetraspanins in cell migration. Cell Adhes Migr. 2015;9:406\u201315.","journal-title":"Cell Adhes Migr"},{"key":"3592_CR26","doi-asserted-by":"crossref","unstructured":"Andreu Z, Y\u00e1\u00f1ez-M\u00f3 M. Tetraspanins in extracellular vesicle formation and function. Front Immunol. 2014;5:442.","DOI":"10.3389\/fimmu.2014.00442"},{"key":"3592_CR27","doi-asserted-by":"crossref","unstructured":"Lombardo SD, Mazzon E, Basile MS, Campo G, Corsico F, Presti M, et al. Modulation of tetraspanin 32 (TSPAN32) expression in T cell-mediated immune responses and in multiple sclerosis. Int J Mol Sci. 2019;20, 4323.","DOI":"10.3390\/ijms20184323"},{"key":"3592_CR28","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","volume":"1","author":"I Solomon","year":"2020","unstructured":"Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat Cancer. 2020;1:1153\u201366.","journal-title":"Nat Cancer"},{"key":"3592_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","volume":"33","author":"TR Malek","year":"2010","unstructured":"Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33:153\u201365.","journal-title":"Immunity"},{"key":"3592_CR30","doi-asserted-by":"crossref","unstructured":"Zhou X, Xing J, Tang X, Sheng X, Chi H, Zhan W. Interleukin-2 (IL-2) interacts with IL-2 receptor beta (IL-2R\u03b2): its potential to enhance the proliferation of CD4+ T lymphocytes in flounder (paralichthys olivaceus). Front Immunol. 2020;11:531785.","DOI":"10.3389\/fimmu.2020.531785"},{"key":"3592_CR31","first-page":"546","volume":"28","author":"MA Perales","year":"2022","unstructured":"Perales MA, Anderson LD Jr, Jain T, Kenderian SS, Oluwole OO, et al. Role of CD19 chimeric antigen receptor t cells in second-line large B cell lymphoma: lessons from phase 3 trials. an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transpl Cell Ther. 2022;28:546\u201359.","journal-title":"Transpl Cell Ther"},{"key":"3592_CR32","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985\u20131005.","journal-title":"Leukemia"},{"key":"3592_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","volume":"34","author":"M D\u2019Agostino","year":"2019","unstructured":"D\u2019Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2019;34:21\u201334.","journal-title":"Leukemia"},{"key":"3592_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2019","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2019;17:147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"3592_CR35","doi-asserted-by":"crossref","unstructured":"Qiu Q, Sun Y, Yang L, Li Q, Feng Y, Li M, et al. TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN. Signal Transduction Targeted Therapy. 2023;8:90.","DOI":"10.1038\/s41392-022-01290-7"},{"key":"3592_CR36","doi-asserted-by":"crossref","unstructured":"Gumber D, Wang LD. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. eBioMedicine. 2022;77:103941.","DOI":"10.1016\/j.ebiom.2022.103941"},{"key":"3592_CR37","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1016\/j.celrep.2019.10.119","volume":"29","author":"BS Marro","year":"2019","unstructured":"Marro BS, Zak J, Zavareh RB, Teijaro JR, Lairson LL, Oldstone MBA. Discovery of small molecules for the reversal of T cell exhaustion. Cell Rep. 2019;29:3293\u20133302.e3.","journal-title":"Cell Rep"},{"key":"3592_CR38","doi-asserted-by":"crossref","unstructured":"Luo M, Gong W, Zhang Y, Li H, Ma D, Wu K, et al. New insights into the stemness of adoptively transferred T cells by \u03b3c family cytokines. Cell Commun Signal. 2023;21:347.","DOI":"10.1186\/s12964-023-01354-3"},{"key":"3592_CR39","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/ni.3540","volume":"17","author":"T Chinen","year":"2016","unstructured":"Chinen T, Kannan AK, Levine AG, Fan X, Klein U, Zheng Y, et al. An essential role for the IL-2 receptor in Treg cell function. Nat Immunol. 2016;17:1322\u201333.","journal-title":"Nat Immunol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03592-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03592-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:06:35Z","timestamp":1789823195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03592-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":39,"alternative-id":["3592"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03592-x","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Blood samples from healthy donors were obtained from volunteers, and blood samples and tumor tissues from cancer patients were acquired from West China Hospital and approved by the clinical ethics committee at West China Hospital, Sichuan University. All patients signed the informed consent form and met all requirements of the Declaration of Helsinki. All animal experiments were conducted in strict accordance with the approved guidelines set forth by the Institutional Animal Care and Use Committees of Sichuan University.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}